Items per page
Sort by

Send to:

Choose Destination

Results: 6

Cited In for PubMed (Select 2009033)


Reducing the Burden of Difficult-to-Treat Major Depressive Disorder: Revisiting Monoamine Oxidase Inhibitor Therapy.

Culpepper L.

Prim Care Companion CNS Disord. 2013;15(5). pii: PCC.13r01515. doi: 10.4088/PCC.13r01515. Epub 2013 Oct 31.


Sertraline versus other antidepressive agents for depression.

Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, McGuire H, Barbui C.

Cochrane Database Syst Rev. 2010 Apr 14;(4):CD006117. doi: 10.1002/14651858.CD006117.pub4. Review.


Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder.

Papakostas GI, Fava M.

Dialogues Clin Neurosci. 2008;10(4):439-51. Review.


An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features.

Pae CU, Masand PS, Peindl K, Mannelli P, Han C, Marks DM, Patkar AA.

Prim Care Companion J Clin Psychiatry. 2008;10(3):205-10.


Is atypical depression a moderate severity depression? A 536-case study.

Benazzi F.

J Psychiatry Neurosci. 1999 May;24(3):244-7. Erratum in: J Psychiatry Neurosci 2000 Mar;25(2):116.


Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial.

Jarrett RB, Schaffer M, McIntire D, Witt-Browder A, Kraft D, Risser RC.

Arch Gen Psychiatry. 1999 May;56(5):431-7.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk